Nathaniel Katz

Summary

Publications

  1. doi Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA, USA
    Postgrad Med 122:112-28. 2010
  2. pmc Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions
    Nathaniel P Katz
    Analgesic Solutions, 232 Pond Street, Natick, MA, 01760, USA
    J Orthop Surg Res 10:24. 2015
  3. pmc Prescription opioid abuse: challenges and opportunities for payers
    Nathaniel P Katz
    Tufts University School of Medicine, Tufts Health Care Institute Program on Opioid Risk Management, Boston, MA, USA
    Am J Manag Care 19:295-302. 2013
  4. doi The measurement of symptoms and side effects in clinical trials of chronic pain
    Nathaniel P Katz
    Program on Opioid Risk Management, Tufts University School of Medicine, Boston, MA 02111, USA
    Contemp Clin Trials 33:903-11. 2012
  5. doi Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions
    Nathaniel Katz
    Analgesic Solutions, Natick, MA, USA
    Am J Drug Alcohol Abuse 37:205-17. 2011
  6. doi ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety
    Nathaniel Katz
    Tufts University School of Medicine, Boston, Massachusetts Analgesic Research, Needham, MA 02494, USA
    J Pain 11:303-11. 2010
  7. ncbi Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials
    Nathaniel Katz
    Harvard Medical School, Boston, Massachusetts 02464, USA
    Curr Med Res Opin 20:651-8. 2004
  8. doi Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction
    Alan G White
    Analysis Group, Inc, Boston, Massachusetts, USA
    Appl Health Econ Health Policy 7:61-70. 2009
  9. ncbi Role of urine toxicology testing in the management of chronic opioid therapy
    Nathaniel Katz
    Pain Trials Center, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin J Pain 18:S76-82. 2002
  10. ncbi Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials
    Nathaniel Katz
    Pain Trials Center, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Spine (Phila Pa 1976) 28:851-8; discussion 859. 2003

Collaborators

Detail Information

Publications27

  1. doi Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA, USA
    Postgrad Med 122:112-28. 2010
    ....
  2. pmc Determining the clinical importance of treatment benefits for interventions for painful orthopedic conditions
    Nathaniel P Katz
    Analgesic Solutions, 232 Pond Street, Natick, MA, 01760, USA
    J Orthop Surg Res 10:24. 2015
    ..Orthopedic surgeons that will use these metrics need to carefully understand them and be aware of their pitfalls. ..
  3. pmc Prescription opioid abuse: challenges and opportunities for payers
    Nathaniel P Katz
    Tufts University School of Medicine, Tufts Health Care Institute Program on Opioid Risk Management, Boston, MA, USA
    Am J Manag Care 19:295-302. 2013
    ..This manuscript's objective is to provide payers with strategies to control these costs, while supporting safe use of prescription opioid medications for patients with chronic pain...
  4. doi The measurement of symptoms and side effects in clinical trials of chronic pain
    Nathaniel P Katz
    Program on Opioid Risk Management, Tufts University School of Medicine, Boston, MA 02111, USA
    Contemp Clin Trials 33:903-11. 2012
    ....
  5. doi Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions
    Nathaniel Katz
    Analgesic Solutions, Natick, MA, USA
    Am J Drug Alcohol Abuse 37:205-17. 2011
    ..Transdermal and solid oral prescription opioid (PO) formulations can be abused by ingesting (with or without tampering), snorting, or injection (both requiring tampering)...
  6. doi ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety
    Nathaniel Katz
    Tufts University School of Medicine, Boston, Massachusetts Analgesic Research, Needham, MA 02494, USA
    J Pain 11:303-11. 2010
    ..4; ALO-01, 2.3, P = .31), WOMAC change-from-baseline (mean pain, physical function, composite scores), and adverse event frequency were similar. ALO-01 and ERMS provided similar relief of osteoarthritis pain...
  7. ncbi Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trials
    Nathaniel Katz
    Harvard Medical School, Boston, Massachusetts 02464, USA
    Curr Med Res Opin 20:651-8. 2004
    ..The objectives of this report are to present data regarding the onset of efficacy of rofecoxib from these trials and propose methods for reporting onset...
  8. doi Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction
    Alan G White
    Analysis Group, Inc, Boston, Massachusetts, USA
    Appl Health Econ Health Policy 7:61-70. 2009
    ..As well as public health and safety benefits, use of an abuse-deterrent/resistant RxO (ADO) that may deter abuse, dependence and misuse could also generate cost savings...
  9. ncbi Role of urine toxicology testing in the management of chronic opioid therapy
    Nathaniel Katz
    Pain Trials Center, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Clin J Pain 18:S76-82. 2002
    ..The authors conclude that, although further research is urgently needed, at this time it is appropriate to conduct routine urine toxicology testing in patients with chronic pain treated with opioids...
  10. ncbi Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials
    Nathaniel Katz
    Pain Trials Center, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Spine (Phila Pa 1976) 28:851-8; discussion 859. 2003
    ..Two replicate, 4-week, randomized, double-blind, placebo-controlled, trials of rofecoxib 25 and 50 mg versus placebo for chronic low back pain...
  11. ncbi A 12-week, randomized, placebo-controlled trial assessing the safety and efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA, USA
    Curr Med Res Opin 23:117-28. 2007
    ..Determine the efficacy and tolerability of oxymorphone extended release (OPANA ER) in opioid-naive patients with moderate to severe chronic low back pain (CLBP)...
  12. doi Enriched enrollment randomized withdrawal trial designs of analgesics: focus on methodology
    Nathaniel Katz
    Analgesic Research, Needham, MA, 02494, USA
    Clin J Pain 25:797-807. 2009
    ..To systematically identify and critically assess clinical trials that use enriched enrollment randomized withdrawal (EERW) trial design as a methodology for assessing the effect of analgesics pain...
  13. ncbi Preliminary development of a responder index for chronic low back pain
    Lee S Simon
    Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02465, USA
    J Rheumatol 34:1386-91. 2007
    ..The aim of the OMERACT Special Interest Group was to discuss the development and validation of a preliminary responder index in CLBP...
  14. doi Usefulness of prescription monitoring programs for surveillance--analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA 02111, USA
    Pharmacoepidemiol Drug Saf 19:115-23. 2010
    ..We analyze herein 11 years of Massachusetts PMP data to evaluate trends in opioid prescribing, dispensing, and usage...
  15. ncbi Methodological issues in clinical trials of opioids for chronic pain
    Nathaniel Katz
    Tufts University School of Medicine, Boston, MA, USA
    Neurology 65:S32-49. 2005
    ..Opioid analgesics should be studied in a manner that is clinically relevant, and that supports internal validity. More systematic attention is needed to clinical research methodology...
  16. ncbi Coxibs: Evolving role in pain management
    Nathaniel Katz
    Department of Anesthesia, Harvard Medical School, Boston, MA, USA
    Semin Arthritis Rheum 32:15-24. 2002
    ..Decreased GI and antiplatelet effects of coxibs compared to traditional NSAIDs provide the potential to incorporate coxibs into the pain management algorithm used to treat cancer pain...
  17. pmc Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers
    Stephen F Butler
    Pain and Opioid Division, Inflexxion Inc, Newton, MA, USA
    Harm Reduct J 3:5. 2006
    ..We developed a scale to measure the 'attractiveness' of prescription opioids to potential abusers, and used the scale to measure the relative attractiveness of 14 opioid analgesic products...
  18. doi Development of a bedside pain assessment kit for the classification of patients with osteoarthritis
    Eric Osgood
    Analgesic Solutions, 232 Pond Street, Natick, MA, 01760, USA
    Rheumatol Int 35:1005-13. 2015
    ..Further research is needed to confirm these subgroups and determine their validity in predicting response to treatment...
  19. doi Efficacy and safety of tanezumab in the treatment of chronic low back pain
    Nathaniel Katz
    Analgesic Solutions, Needham, MA 02494, USA
    Pain 152:2248-58. 2011
    ..Tanezumab clinical development is on regulatory hold due to AEs in osteoarthritis patients...
  20. pmc Efficacy and tolerability of buccal buprenorphine in opioid-experienced patients with moderate to severe chronic low back pain: results of a phase 3, enriched enrollment, randomized withdrawal study
    Joseph Gimbel
    aArizona Research Center, Phoenix, AZ, USA bDepartment of Neurology, Craniofacial Pain Center, Tufts University Schools of Medicine and Dental Medicine, Boston, MA, USA cAnalgesic Solutions, LLC, Natick, MA, USA dTufts University, Boston, MA, USA eEndo Pharmaceuticals Inc, Malvern, PA, USA fFormerly of Endo Pharmaceuticals Inc, Malvern, PA, USA gBioDelivery Sciences International Inc, Raleigh, NC, USA
    Pain 157:2517-2526. 2016
    ..5% vs 2.3%). These findings demonstrate the efficacy and tolerability of BBUP in opioid-experienced patients taking around-the-clock opioid treatment for chronic low back pain...
  21. doi Efficacy and safety of tanezumab in the treatment of pain from bone metastases
    Maciej Sopata
    aDepartment of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland bAnalgesic Solutions, Natick, MA, USA cDepartment of Anesthesiology, Tufts University School of Medicine, Boston, MA, USA dPfizer Inc, Groton, CT, USA
    Pain 156:1703-13. 2015
    ..Although the primary endpoint was not achieved, tanezumab may provide additional sustained analgesia in patients with metastatic bone pain taking daily opioids. Additional larger studies are warranted. ..
  22. doi A review of the use of the number needed to treat to evaluate the efficacy of analgesics
    Nathaniel Katz
    Analgesic Solutions, Natick, Massachusetts
    J Pain 16:116-23. 2015
    ..Nevertheless, efficacy, as measured by any variable, is only one aspect of a treatment to be considered in determining its place in therapy...
  23. ncbi The impact of pain management on quality of life
    Nathaniel Katz
    Pain Trials Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Pain Symptom Manage 24:S38-47. 2002
    ....
  24. doi The impact of opioids on the endocrine system
    Nathaniel Katz
    Analgesic Research, Tufts University School of Medicine, Boston, MA, USA
    Clin J Pain 25:170-5. 2009
    ..However, their negative effects on the endocrine system, which have been known for some times, are barely discussed in modern medicine. Therefore, we conducted a systematic review of the impact of opioids on the endocrine system...
  25. doi Ultrasound-enabled topical anesthesia for pain reduction of phlebotomy for whole blood donation
    Christopher P Stowell
    Department of Pathology, Blood Transfusion Service, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Transfusion 49:146-53. 2009
    ..Ultrasound-facilitated delivery of topical anesthetics has been used to achieve effective anesthesia within 5 minutes for venipuncture and the insertion of intravenous access devices, but has never been studied for blood donation...
  26. doi Illustration of a statistical process control approach to regional prescription opioid abuse surveillance
    James C Benneyan
    Center for Health Organization Transformation, Northeastern University, Boston, MA, USA
    J Addict Med 5:99-109. 2011
    ..To investigate and illustrate the use of statistical process control (SPC) for prospective monitoring and detection of regional changes in prescription opioid abuse rates...
  27. ncbi Direct costs of opioid abuse in an insured population in the United States
    Alan G White
    Analysis Group, Inc, 111 Huntington Ave, 10th Fl, Boston, MA 02199, USA
    J Manag Care Pharm 11:469-79. 2005
    ..g., inpatient, outpatient, emergency room, drug, other) from the perspective of a private payer...